BB BIOTECH AG Disclaimer This release contains forward-looking statements and expectations as well as assessments, beliefs and assumptions. Such statements are based on the current expectations of BB Biotech, its directors and officers, and are, therefore, subject to risks and uncertainties that may change over time. As actual developments may significantly differ, BB Biotech and its directors and officers accept no responsibility in that regard. All forward-looking statements included in this release are made only as of the date of this release and BB Biotech and its directors and officers assume no obligation to update any forward-looking statements as a result of new information, future events or other factors. Composition of BB Biotech's portfolio as at September 30, 2021 (in % of securities, rounded values)
Moderna 14.7% Ionis Pharmaceuticals 7.0% Argenx SE 6.6% Neurocrine Biosciences 6.4% Alnylam Pharmaceuticals 4.8% Incyte 4.5% Agios Pharmaceuticals 4.5% Vertex Pharmaceuticals 4.3% Fate Therapeutics 4.3% Arvinas 4.1% Macrogenics 3.4% Biogen 3.2% Sage Therapeutics 3.2% Intra-Cellular Therapies 3.1% Myovant Sciences 2.9% Relay Therapeutics 2.7% Crispr Therapeutics 2.4% Radius Health 2.2% Revolution Medicines 2.1% Scholar Rock Holding 1.7% Molecular Templates 1.6% Generation Bio Co. 1.4% Exelixis 1.4% Esperion Therapeutics 1.2% Beam Therapeutics 1.2% Nektar Therapeutics 1.1% Essa Pharma 0.9% Kezar Life Sciences 0.9% Mersana Therapeutics 0.9% Black Diamond Therapeutics 0.7% Homology Medicines 0.3% Wave Life Sciences 0.3% Alder Biopharmaceuticals - CVR 0.1% Total securities CHF 4 093.1 mn Other assets CHF 1.9 mn Other liabilities CHF (261.8) mn Net Asset Value CHF 3 833.2 mn
-----------------------------------------------------------------------------------------------------------------------
2021-10-22 Dissemination of a Corporate News, transmitted by DGAP - a service of EQS Group AG. The issuer is solely responsible for the content of this announcement. The DGAP Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases. Archive at www.dgap.de
-----------------------------------------------------------------------------------------------------------------------
Language: English
Company: BB BIOTECH AG
Schwertstrasse 6
8200 Schaffhausen
Switzerland
Phone: +41 52 624 08 45
E-mail: info@bbbiotech.com
Internet: www.bbbiotech.ch
ISIN: CH0038389992
WKN: A0NFN3
Listed: Regulated Market in Frankfurt (Prime Standard); Mailand, SIX
EQS News ID: 1242645
End of News DGAP News Service
=------------ 1242645 2021-10-22
Image link: https://eqs-cockpit.com/cgi-bin/fncls.ssp?fn=show_t_gif&application_id=1242645&application_name=news
(END) Dow Jones Newswires
October 22, 2021 05:16 ET (09:16 GMT)
